Cat. No.: HY-15721

Copy Link Print Information

FH535

20 Cited Publications

Avis client

Based on 20 publication(s) in Google Scholar

FH535 is an inhibitor of Wnt/β-catenin and PPAR with anti-tumor activities.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.95%
CAS No.: 108409-83-2
Formule: C₁₃H₁₀Cl₂N₂O₄S
Masse moléculaire:361.20

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

FH535 Chemical Structure

CAS No.: 108409-83-2

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (20)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

FH535 is an inhibitor of Wnt/β-catenin and PPAR with anti-tumor activities^[1].

IC₅₀ & Target^[1]

PPAR

β-catenin

Voir tous les produits spécifiques à Isoform PPAR :

Voir tous les produits spécifiques à Isoform Wnt :

Cellular Effect

Cell Line	Type	Value	Description	References
DLD-1	IC₅₀	28 μM Compound: 16; FH535	Growth inhibition of human DLD1 cells without NHERF1 expression incubated for 72 hrs by MTT assay Growth inhibition of human DLD1 cells without NHERF1 expression incubated for 72 hrs by MTT assay	[PMID: 30996786]
SW480	IC₅₀	10 μM Compound: 16; FH535	Growth inhibition of human SW480 cells expressing NHERF1 incubated for 72 hrs by MTT assay Growth inhibition of human SW480 cells expressing NHERF1 incubated for 72 hrs by MTT assay	[PMID: 30996786]

In Vitro

FH535 is an inhibitor of Wnt/β-catenin and PPAR. FH535 inhibits PPARγ and PPARδ transactivation in HCT116 cells. FH535 (15 μM) activities depend on functional PPARδ but does not require a cysteine residue in the PPAR ligand-binding domain. FH535 inhibits recruitment of the coactivators GRIP1 and β-catenin to PPARδ and PPARγ. FH535 shows toxic effects on 12 carcinoma cell lines expressing wnt/β-catenin pathway^[1].
FH535 (20 μM) suppresses the β-catenin pathway in pancreatic cancer cells, and inhibits pancreatic cancer cell migration. Furthermore, FH535 (20, 40 μM) inhibits pancreatic cancer cell invasion and cell growth^[2].
FH535 represses angiogenesis-related genes in pancreatic cancer cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

FH535 (25 mg/kg, i.p.) exhibits an anti-tumor effect on pancreatic cancer xenografts in mice. FH535 also represses angiogenesis in pancreatic cancer xenografts^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 108409-83-2
Appearance Solid
Masse moléculaire 361.20
Formule C₁₃H₁₀Cl₂N₂O₄S
Color Light yellow to yellow
SMILES

O=S(C1=CC(Cl)=CC=C1Cl)(NC2=CC=C([N+]([O-])=O)C=C2C)=O
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (20)

All WB

Sort by:

Journal Impact Factor

Exp Mol Med

β-Catenin promotes long-term survival and angiogenesis of peripheral blood mesenchymal stem cells via the Oct4 signaling pathway. [Abstract]

2022 Sep;54(9):1434-1449. PMID: 36050404
Cancer Lett

BET protein-dependent E2F pathway activity confers bell-shaped type resistance to tankyrase inhibitors in APC-mutated colorectal cancer. [Abstract]

2024 Mar 1:584:216632. PMID: 38216082
J Neuroinflammation

Wnt5a/β-catenin-mediated epithelial-mesenchymal transition: a key driver of subretinal fibrosis in neovascular age-related macular degeneration. [Abstract]

2024 Mar 26;21(1):75. PMID: 38532410
Phytomedicine

Study of α-Amyrin targeting Sirt1/PGC-1α/PPARα axis to regulate fatty acid metabolism against liver fibrosis. [Abstract]

2026 Jun 13:159:158432. PMID: 42322765
Drug Deliv Transl Res

Glucocorticoid receptor-targeted liposomal delivery of wnt/β-catenin pathway inhibitor selectively induces efficient colorectal tumor regression. [Abstract]

2025 Aug 18. PMID: 40824413
Mech Ageing Dev

Cyr61 promotes D-gal-induced aging C2C12 cell fibrosis by modulating Wnt/β-catenin signaling pathways. [Abstract]

2025 Jun:225:112067. PMID: 40339921
Int Immunopharmacol

Exosomal miR-3529-3p increases the sensitivity of trastuzumab via Wnt/β-catenin signaling pathway by targeting HOOK3. [Abstract]

2025 Sep 23:162:115160. PMID: 40614603
Invest Ophthalmol Vis Sci

PRMT5 Regulates Senescence in Retinal Ganglion Cells by Targeting the Wnt/β-Catenin Signaling Cascade. [Abstract]

2025 Jun 2;66(6):8. PMID: 40459496
Neurochem Res

MiR-19b-3p Inhibits Hypoxia-Ischemia Encephalopathy by Inhibiting SOX6 Expression via Activating Wnt/β-catenin Pathway. [Abstract]

2023 Mar;48(3):874-884. PMID: 36369428

FH535 purchased from MedChemExpress. Usage Cited in: Neurochem Res. 2023 Mar;48(3):874-884. [Abstract]

FH535 (2.5 µM; 1 h) significantly inhibits β-catenin and cyclin D1 expressions, and attenuates the effect of SOX6 knockdown on Wnt/β-catenin pathway, in OGD/R-triggered HT22 cells.
iScience

PCR-based profiling of transcription factor activity in vivo by a virus-based reporter battery. [Abstract]

2022 Feb 14;25(3):103927. PMID: 35281741
Microb Pathog

Natural small molecule compounds targeting Wnt signaling pathway inhibit HPV infection. [Abstract]

2024 Nov:196:106960. PMID: 39313132
Front Oncol

NRAGE Confers Radiation Resistance in 2D and 3D Cell Culture and Poor Outcome in Patients With Esophageal Squamous Cell Carcinoma. [Abstract]

2022 Apr 1:12:831506. PMID: 35433476
Theriogenology

Aldosterone regulates in vitro maturation of porcine oocytes derived from small follicles via Wnt/ β-catenin. [Abstract]

2026 Apr 15:255:117836. PMID: 41564797
Theriogenology

LIF and bFGF enhanced chicken primordial follicle activation by Wnt/β-catenin pathway. [Abstract]

2021 Dec:176:1-11. PMID: 34555602
Vet Microbiol

β-catenin facilitates fowl adenovirus serotype 4 replication through enhancing virus-induced autophagy. [Abstract]

2023 Jan:276:109617. PMID: 36469999
Vet Microbiol

The canonical Wnt/β-catenin signaling pathway facilitates pseudorabies virus proliferation and enhances virus-induced autophagy. [Abstract]

2022 Sep:272:109502. PMID: 35841697
Cancer Manag Res

miR106a Promotes the Growth of Transplanted Breast Cancer and Decreases the Sensitivity of Transplanted Tumors to Cisplatin. [Abstract]

2020 Jan 13:12:233-246. PMID: 32021439
Oncol Lett

Long non-coding RNA colon cancer-associated transcript 2 may promote esophageal cancer growth and metastasis by regulating the Wnt signaling pathway. [Abstract]

2019 Aug;18(2):1745-1754. PMID: 31423241
Zygote

Expression of lncRNA TINCR in the placenta of patients with pre-eclampsia and its effect on the biological behaviours of trophoblasts. [Abstract]

2022 Feb;30(1):111-119. PMID: 34176530
Int J Biol Sci

Berberine ameliorates DSS-induced intestinal mucosal barrier dysfunction through microbiota-dependence and Wnt/β-catenin pathway. [Abstract]

2022 Jan 16;18(4):1381-1397. PMID: 35280677

Solvant et solubilité

In Vitro:

DMSO : 33.33 mg/mL (92.28 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.7685 mL

13.8427 mL

27.6855 mL

5 mM

0.5537 mL

2.7685 mL

5.5371 mL

10 mM

0.2769 mL

1.3843 mL

2.7685 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 2% DMSO 40% PEG300 5% Tween-80 53% Saline

Solubility: 3 mg/mL (8.31 mM); Suspended solution; Need ultrasonic

Protocol 2

Add each solvent one by one: 2% DMSO 98% Corn Oil

Solubility: ≥ 3 mg/mL (8.31 mM); Clear solution

Protocol 3

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.92 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 4

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (6.92 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocole

Cell Assay^[2]

Cell growth is evaluated using the MTT assay. Cells (5 × 10⁴/well) are seeded in 24-well tissue culture plates. Blank control is treated with DMSO. After FH535 treatment, MTT is added to each well (final concentration, 0.5 mg/mL), followed by 4-hour incubation at 37°C. The medium is removed, and 800 μL of DMSO is added to each well. The absorbance of the mixture is measured at 490 nm using a microplate enzyme-linked immunosorbent assay reader. The relative cell viability is calculated as follows: relative cell viability = (mean experimental absorbance/mean control absorbance) ×100%^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[3]

Four-week-old female BALB/c athymic nude mice receive humane care. PANC-1 cells stably expressing firefly luciferase are injected into the left flanks of the mice in a total volume of 100 μL (0.5 × 10⁷ cells), and the mice are randomly assigned to a DMSO [intraperitoneally injected with 100 μL DMSO/DMEM (1:1)] or FH535 group [intraperitoneally injected with 25 mg/kg FH535 dissolved in 100 μL DMSO/DMEM (1:1)]. Treatment is conducted every 2 days for 20 days; tumor volume is measured with a caliper using the formula: volume = length × width²/2. At the end of the experiment, the mice are anaesthetized and given D-luciferin in PBS. Twenty minutes after the injection, bioluminescence is imaged with a charge-coupled device camera. Then, the tumor tissue is stripped and formalin-fixed, paraffin-embedded, cut into 4-μm sections, and immunohistochemically stained^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (284 KB)
SDS (614 KB)
- English - EN (614 KB)
- Français - FR (614 KB)
- Deutsch - DE (614 KB)
- Norwegian - NO (614 KB)
- Español - ES (614 KB)
- Swedish - SV (614 KB)
- Italian - IT (614 KB)
- Korean - KR (614 KB)
- Portuguese - PT (614 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Handeli S, et al. A small-molecule inhibitor of Tcf/beta-catenin signaling down-regulates PPARgamma and PPARdelta activities. Mol Cancer Ther. 2008 Mar;7(3):521-9. [Content Brief]

[2]. Wu MY, et al. FH535 inhibited metastasis and growth of pancreatic cancer cells. Onco Targets Ther. 2015 Jul 6;8:1651-70. [Content Brief]

[3]. Liu L, et al. FH535, a β-catenin pathway inhibitor, represses pancreatic cancer xenograft growth and angiogenesis. Oncotarget. 2016 Jul 26;7(30):47145-47162. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.7685 mL	13.8427 mL	27.6855 mL	69.2137 mL
	5 mM	0.5537 mL	2.7685 mL	5.5371 mL	13.8427 mL
	10 mM	0.2769 mL	1.3843 mL	2.7685 mL	6.9214 mL
	15 mM	0.1846 mL	0.9228 mL	1.8457 mL	4.6142 mL
	20 mM	0.1384 mL	0.6921 mL	1.3843 mL	3.4607 mL
	25 mM	0.1107 mL	0.5537 mL	1.1074 mL	2.7685 mL
	30 mM	0.0923 mL	0.4614 mL	0.9228 mL	2.3071 mL
	40 mM	0.0692 mL	0.3461 mL	0.6921 mL	1.7303 mL
	50 mM	0.0554 mL	0.2769 mL	0.5537 mL	1.3843 mL
	60 mM	0.0461 mL	0.2307 mL	0.4614 mL	1.1536 mL
	80 mM	0.0346 mL	0.1730 mL	0.3461 mL	0.8652 mL

Keywords

FH535

20 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

FH535

Differentiation Inducing Compound Library

Cytoskeleton Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Nuclear Receptor Compound Library

Cancer Stem Cells Compound Library

Antihypertensive Compound Library

Metabolic Enzyme Compound Library

Extracellular Vesicles (EVs) Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

RNA Binding Bioactive Compound Library

Anti-Aging Compound Library Mini

Cell Cycle/DNA Damage Compound Library

Metabolism/Protease Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Publications Citing Use of MedChemExpress (MCE) FH535

Voir tous les produits spécifiques à Isoform PPAR

Voir tous les produits spécifiques à Isoform Wnt

Activité biologique

Chemical Information

Publications (20)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

FH535 Related Classifications

HY-15721 Related Classifications